Samil Pharmaceutical삼일제약
000520 · KOSPI · ₩000520 · 삼일제약
- Market cap
- ₩169B
- Enterprise value
- ₩337B
- P/E
- —
- P/B
- 1.3×
- Dividend yield
- 0.0%
- ROE
- −30.0%
- Net margin
- −18.1%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−39.5% from the high
₩5,500Today: ₩7,650 – ₩8,030₩12,860
Returns
- 1W−5.6%
- 1M−5.1%
- 3M+33.4%
- 6M−14.5%
- YTD−19.7%
- 1Y−21.3%
- Volume today
- 52,953
- 0.8× the 20-day average
- Traded today
- ₩415M
- Listed shares
- 21,691,811
- EPS (12 months)
- −₩1,734
- Earnings yield −22.3%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 40 of 100 (50 is a normal day for this stock).
- MomentumFlat-4% over the last month; the price is below its 20-day average.
- News impactLow1 news items and filings in two weeks; 0 rated high impact, 0 medium.
Signals describe activity, not recommendations. Not financial advice.
Samil Pharmaceutical stock overview
Samil Pharmaceutical (삼일제약, KRX: 000520) is listed on KOSPI, in the Biotech & Pharma sector. Samil Pharmaceutical is a Korean pharmaceutical company founded in 1947 that manufactures and sells prescription drugs, known for products such as children's ibuprofen syrup, Tear Once One, and Aitooh Mini. Its shares closed at ₩7,780 on Oct 28, 2026, up 1.83% on the day, giving it a market value of ₩169B.
Key facts
- Market cap
- ₩169B
- Sector
- Biotech & Pharma
- Latest price change
- +1.83%
- As of
- Oct 28, 2026
- Main business
- Samil Pharmaceutical is a Korean pharmaceutical company founded in 1947 that manufactures and sells prescription drugs, known for products such as children's ibuprofen syrup, Tear Once One, and Aitooh Mini.
Quick answers about Samil Pharmaceutical
- What does Samil Pharmaceutical do?
- Samil Pharmaceutical is a Korean pharmaceutical company founded in 1947 that manufactures and sells prescription drugs, known for products such as children's ibuprofen syrup, Tear Once One, and Aitooh Mini. It focuses on ophthalmology, liver disease, and digestive system medicines, developing and producing generic and improved drugs, and also importing and exclusively distributing original products in Korea. The company operates through its pharmaceutical business and other business segments, and its subsidiary SAMIL PHARMACEUTICAL COMPANY LIMITED in Vietnam runs a global ophthalmic contract development and manufacturing facility.
- What is the market cap of Samil Pharmaceutical?
- The market capitalisation of Samil Pharmaceutical was ₩169B at the close on Oct 28, 2026.
- Who are the largest shareholders of Samil Pharmaceutical?
- According to the latest official filings, the largest reported holders are Heo Seung-beom (25.96%, as of Oct 12, 2026); Heo Jun-beom (1.56%, as of May 15, 2025); National Pension Service (0.67%, as of Dec 31, 2025).
- When is the next earnings report from Samil Pharmaceutical?
- Korean companies rarely announce results dates in advance. Based on when Samil Pharmaceutical filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
- Does the National Pension Service own Samil Pharmaceutical?
- Yes. The National Pension Service held 0.67% of Samil Pharmaceutical shares as of Dec 31, 2025.
Company profile
Samil Pharmaceutical is a Korean pharmaceutical company founded in 1947 that manufactures and sells prescription drugs, known for products such as children's ibuprofen syrup, Tear Once One, and Aitooh Mini. It focuses on ophthalmology, liver disease, and digestive system medicines, developing and producing generic and improved drugs, and also importing and exclusively distributing original products in Korea. The company operates through its pharmaceutical business and other business segments, and its subsidiary SAMIL PHARMACEUTICAL COMPANY LIMITED in Vietnam runs a global ophthalmic contract development and manufacturing facility.
Written by AI from the company's latest annual report.
- Korean name
- 삼일제약
- Sector
- Biotech & Pharma
- Themes
- Pharmaceuticals
- CEO
- 허승범
- Founded
- Oct 1947
- Listed
- May 1985
- Listed shares
- 21,691,811
- Fiscal year ends
- Month 12
- Website
- www.samil-pharm.com
Similar companies
- Samsung Biologics207940 · ₩64T₩1,372,000−0.15%
- Celltrion068270 · ₩44T₩189,800+0.64%
- Alteogen196170 · ₩16T₩223,000+2.06%
- SK biopharmaceuticals326030 · ₩5.9T₩75,200+0.40%
- Yuhan000100 · ₩5.7T₩77,300−3.38%
- HLB028300 · ₩5.4T₩40,650+1.88%
- Hanmi Pharm128940 · ₩4.7T₩369,500+5.42%
- SAM Chun Dang Pharm000250 · ₩4.5T₩190,000+1.28%
Recent filings
See all- Insider shareholding reportOct 19, 2026
- 5%+ holding reportOct 12, 2026
- Added attachment: Half-year report (Jun 2026)Aug 14, 2026
- 5%+ holding reportJul 21, 2026
- Insider shareholding reportJul 1, 2026
Titles in Korean until English translations are added.
Also known as: Samil Pharmaceutical / 삼일제약 / 000520 / KRX:000520
Source: KRX statistical information